PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Alex F. Herrera, Yi‐Bin Chen et al.|Blood|2019Cited by 187
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W. Merryman, Eric D. Jacobsen, Natasha Edwin et al.|Blood Advances|2020Cited by 58
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patientsMatthew S. Davids, Jennifer R. Brown, David C. Fisher et al.|Leukemia|2020Cited by 36
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Jennifer R. Brown, Alec Griffith et al.|Leukemia|2021Cited by 20
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W. Merryman, Philippe Armand, Erin M. Parry et al.|Blood Advances|2022Cited by 19